Lazard Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16.4M | Buy |
124,479
+59,554
| +92% | +$7.9M | 0.03% | 355 |
|
|
2025
Q4 | $9.21M | Buy |
64,925
+24,048
| +59% | +$3.48M | 0.02% | 426 |
|
|
2025
Q3 | $5.74M | Buy |
40,877
+4,503
| +12% | +$610K | 0.01% | 543 |
|
|
2025
Q2 | $4.57M | Sell |
36,374
-20,408
| -36% | -$2.34M | 0.01% | 755 |
|
|
2025
Q1 | $6.28M | Sell |
56,782
-2,497
| -4% | -$316K | 0.01% | 617 |
|
|
2024
Q4 | $8.09M | Sell |
59,279
-15,643
| -21% | -$1.93M | 0.01% | 519 |
|
|
2024
Q3 | $8.63M | Buy |
74,922
+13,489
| +22% | +$1.85M | 0.01% | 490 |
|
|
2024
Q2 | $8.46M | Buy |
61,433
+6,104
| +11% | +$837K | 0.01% | 546 |
|
|
2024
Q1 | $7.63M | Buy |
55,329
+8,884
| +19% | +$1.21M | 0.01% | 597 |
|
|
2023
Q4 | $6.12M | Buy |
46,445
+19,192
| +70% | +$2.21M | 0.01% | 646 |
|
|
2023
Q3 | $3.06M | Buy |
27,253
+25,393
| +1,365% | +$2.67M | ﹤0.01% | 801 |
|
|
2023
Q2 | $175K | Sell |
1,860
-43,127
| -96% | -$4.21M | ﹤0.01% | 1382 |
|
|
2023
Q1 | $4.55M | Buy |
44,987
+40,752
| +962% | +$4.24M | 0.01% | 747 |
|
|
2022
Q4 | $505K | Buy |
4,235
+3,032
| +252% | +$355K | ﹤0.01% | 1123 |
|
|
2022
Q3 | $127K | Buy |
1,203
+438
| +57% | +$44.4K | ﹤0.01% | 1377 |
|
|
2022
Q2 | $74K | Sell |
765
-26
| -3% | -$2.4K | ﹤0.01% | 1633 |
|
|
2022
Q1 | $74K | Sell |
791
-47,717
| -98% | -$4.04M | ﹤0.01% | 1538 |
|
|
2021
Q4 | $4.13M | Buy |
48,508
+14,394
| +42% | +$1.32M | ﹤0.01% | 808 |
|
|
2021
Q3 | $3.27M | Buy |
+34,114
| New | +$3.22M | ﹤0.01% | 840 |
|
|
2021
Q2 | – | Sell |
-915
| Closed | -$88K | – | 2037 |
|
|
2021
Q1 | $88K | Sell |
915
-73
| -7% | -$7.66K | ﹤0.01% | 1230 |
|
|
2020
Q4 | $94K | Buy |
988
+28
| +3% | +$2.7K | ﹤0.01% | 1200 |
|
|
2020
Q3 | $92K | Sell |
960
-212
| -18% | -$24.5K | ﹤0.01% | 1039 |
|
|
2020
Q2 | $142K | Sell |
1,172
-641
| -35% | -$70.8K | ﹤0.01% | 960 |
|
|
2020
Q1 | $156K | Buy |
1,813
+1,259
| +227% | +$123K | ﹤0.01% | 929 |
|
|
2019
Q4 | $59K | Sell |
554
-886
| -62% | -$92.8K | ﹤0.01% | 1023 |
|
|
2019
Q3 | $129K | Buy |
1,440
+340
| +31% | +$31.8K | ﹤0.01% | 963 |
|
|
2019
Q2 | $92K | Hold |
1,100
| – | – | ﹤0.01% | 1096 |
|
|
2019
Q1 | $96K | Hold |
1,100
| – | – | ﹤0.01% | 1037 |
|
|
2018
Q4 | $78K | Buy |
+1,100
| New | +$105K | ﹤0.01% | 924 |
|
|
2018
Q3 | – | Sell |
-10,534
| Closed | -$1.03M | – | 1087 |
|
|
2018
Q2 | $1.03M | Buy |
+10,534
| New | +$943K | ﹤0.01% | 721 |
|
|
2017
Q2 | – | Sell |
-12,700
| Closed | -$549K | – | 1033 |
|
|
2017
Q1 | $549K | Sell |
12,700
-1,500
| -11% | -$64.3K | ﹤0.01% | 738 |
|
|
2016
Q4 | $549K | Sell |
14,200
-34,443
| -71% | -$1.56M | ﹤0.01% | 731 |
|
|
2016
Q3 | $2.46M | Sell |
48,643
-19,041
| -28% | -$948K | ﹤0.01% | 604 |
|
|
2016
Q2 | $3.08M | Buy |
+67,684
| New | +$3.12M | 0.01% | 572 |
|
|
2016
Q1 | – | Sell |
-3,355
| Closed | -$189K | – | 1085 |
|
|
2015
Q4 | $189K | Sell |
3,355
-2,525
| -43% | -$128K | ﹤0.01% | 828 |
|
|
2015
Q3 | $233K | Buy |
5,880
+1,490
| +34% | +$72K | ﹤0.01% | 763 |
|
|
2015
Q2 | $209K | Buy |
4,390
+425
| +11% | +$18K | ﹤0.01% | 833 |
|
|
2015
Q1 | $157K | Buy |
+3,965
| New | +$142K | ﹤0.01% | 876 |
|
Other funds holding NBIX
VPM
VCM
Lazard Asset Management's NBIX Position: Q1 2026 in Review
Lazard Asset Management increased its Neurocrine Biosciences (NBIX) stake by 92% in Q1 2026, buying an estimated $7.9M and bringing the position to 124,479 shares worth $16.4M. The position accounts for 0.03% of the portfolio, ranked #355.
Lazard Asset Management first reported a position in NBIX in Q1 2015 and has held it in 38 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Lazard Asset Management held 124,479 shares of Neurocrine Biosciences worth $16.4M as of Q1 2026.
- Lazard Asset Management bought 59,554 Neurocrine Biosciences shares in Q1 2026, an estimated $7.9M.
- Neurocrine Biosciences made up 0.03% of Lazard Asset Management's portfolio in Q1 2026, its #355 holding.
- Lazard Asset Management first reported a position in Neurocrine Biosciences in Q1 2015 and has held it in 38 quarters since.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.